Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2025-05-12 Interim / Quarterly Rep…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Pharmanutra: CdA approva il Resoconto intermedio di gestione al 31 marzo 2025
Interim / Quarterly Report Classification · 1% confidence The document is an official announcement from PharmaNutra S.p.A. regarding the approval of its 'Resoconto Intermedio di Gestione' (Interim Management Report) for the period ending March 31, 2025. It contains substantive financial data, including consolidated income statements, balance sheets, and management commentary on performance. While it is presented as a press release, it provides the actual financial results for the quarter, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-12 Italian
Pharmanutra: BoD approves the Intermin management report as of March 31, 2025
Earnings Release Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing the approval of their Interim Management Report for the period ending March 31, 2025. While it contains summary financial tables and highlights, it is structured as an earnings release announcement (press release format) rather than the full, formal interim report document itself. It includes a certification by the executive in charge and provides key performance indicators (KPIs) for the quarter. Based on the 'Menu vs Meal' rule, this is an Earnings Release (ER) as it provides the initial announcement and highlights of the quarterly financial results. Q1 2025
2025-05-12 English
Allegato 3F - Aprile 2025
Director's Dealing Classification · 1% confidence The document is a structured disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Model Disclosure for Transactions in the Issuer's Securities). It details transactions involving the issuer's shares (Pharmanutra S.p.A.) conducted by a third party (Intermonte SPA) during a specific reference period (April 2025, reported May 6, 2025). This type of filing, which reports personal share transactions by executives or related parties (though here it seems to be an intermediary reporting on behalf of or related to the issuer's shares), strongly aligns with insider trading or director's dealing disclosures, especially given the detailed transaction breakdown. Reviewing the definitions: - 10-K/IR: Not a full annual or interim report. - ER/MRQ: Not an earnings release. - DIV/CAP/SHA: Not primarily about dividends, general financing, or capital structure changes. - DIRS (Director's Dealing): This category covers reports of personal share transactions by company directors and executives (insider trades). While the reporting party here is 'INTERMONTE SPA', the context of reporting specific daily transactions in the issuer's stock (Pharmanutra) using a standardized regulatory schema strongly suggests a filing related to insider activity or significant share movements that require mandatory disclosure, which is often grouped with DIRS or similar transaction reports. - POS (Transaction in Own Shares): This is for the company buying back or selling its own shares, not typically for third-party transactions in the stock unless explicitly stated. Given the detailed reporting of daily purchases/sales of the issuer's stock (A/V = Purchase/Sale) by a related entity, this fits best under the umbrella of transactions by insiders or related parties. In many regulatory frameworks, these transaction reports are classified similarly to Director's Dealing (DIRS). Since the document explicitly details transactions in the issuer's securities, and it is a formal regulatory disclosure (Informazione Regolamentata), DIRS is the most appropriate fit among the provided options for reporting significant security transactions by parties connected to the issuer, even if the reporting party isn't strictly a director in this specific table section.
2025-05-06 Italian
PHARMANUTRA: Voting Summary Report
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text details the voting results for various agenda items ('Point 1.1 of the ordinary part', 'Point 2.1 of the ordinary part', etc.) presented to a shareholders' meeting. Key topics include the approval of Financial Statements, allocation of profit, remuneration policy votes, appointment of auditors, authorization for treasury share purchase, and amendments to the Articles of Association. The structure, which lists specific resolutions and the corresponding vote tallies (Favorable, Opposite, Abstainer), is characteristic of the official minutes or results declaration following a General Meeting. Since the document explicitly details the voting outcomes for resolutions passed at a meeting, it aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the Annual Report (10-K) itself, nor is it a general proxy solicitation (PSI), but the record of the results.
2025-04-22 English
Pharmanutra: Rendiconto sintetico delle votazioni
AGM Information Classification · 1% confidence The document text consists of detailed voting results ('n. azioni', 'Favorevole', 'Contrario', 'Astenuto') for several agenda items ('Punto 1.1', 'Punto 1.2', etc.) of a meeting concerning the approval of the Financial Statements ('Bilancio di esercizio'), remuneration policy, appointment of the Board of Statutory Auditors ('Collegio Sindacale'), authorization for share buybacks ('acquisto... di azioni ordinarie proprie'), and sustainability reporting attestation. The structure, the presence of quorum calculations, and the focus on voting outcomes strongly indicate this is a record of decisions made during a shareholder meeting. The closest fit among the provided codes is 'AGM-R' (AGM Information), as these are the typical materials presented and voted upon at an Annual General Meeting (AGM). While it contains voting results (which could suggest DVA), the context is the entire set of resolutions presented at the meeting, making AGM-R more appropriate for the overall document type.
2025-04-22 Italian
Pharmanutra S.p.A.: Rendiconto sintetico delle votazioni (ITA/ENG)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Pharmanutra S.p.A.: Rendiconto sintetico delle votazioni (ITA/ENG)' and explicitly states it is the 'RENDICONTO SINTETICO DELLE VOTAZIONI' (Summary Report of Voting Results) from the Shareholders' Meeting held on April 16, 2025. This document reports the outcome of shareholder votes, which directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements'. The filing type code for this is DVA.
2025-04-22 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.